Compensation Without Capitulation: Designing Vaccine Injury Schemes That Serve Both Justice and Public Health

By Prof. Giorgi Pkhakadze, MD, MPH, PhD
Editor-in-Chief, Georgian Medical Journal

The promised overhaul of the United Kingdom’s COVID-19 vaccine injury compensation scheme represents far more than a domestic policy correction. It is a critical juncture for global vaccine policy. How Britain redesigns its framework will reverberate across health systems worldwide—shaping not only how other nations structure their own compensation mechanisms, but whether publics maintain confidence in vaccination as a public health tool.

The stakes could hardly be higher. When compensation schemes fail victims—through bureaucratic delay, evidentiary barriers, or perceived indifference—the damage extends well beyond individual cases. It catalyzes doubt. It feeds narratives that institutions prioritize vaccines over people. And in our hyperconnected world, that doubt travels instantly across borders, influencing vaccination decisions in Georgia, in Germany, in Ghana.

Yet the inverse risk is equally grave. If compensation schemes are reformed in ways that decouple injury causation from rigorous evidence, we risk creating frameworks that conflate temporal association with causation, that reward litigation strategy over scientific investigation, and that inadvertently validate the very hesitancy campaigns we seek to counter. A compensation scheme that becomes a vehicle for unsubstantiated claims undermines the evidence base that vaccination itself depends upon.

I do not say this lightly. I have reviewed the testimony concerning vaccine injury cases—genuine cases, tragic cases, that deserved more timely and compassionate response than they received. The failure was not in acknowledging harm; it was in the machinery of acknowledgment. Victims faced delays measured in years. Documentation was treated as adversarial rather than investigative. The scheme became a barrier rather than a bridge.

This must change. But it must change intelligently.

Reform should rest on four foundations:

First, expedited but rigorous causality assessment. Compensation should not require the same evidentiary standard as criminal conviction, yet neither should temporal proximity alone suffice. Independent, expert review boards—insulated from both pharmaceutical industry interests and anti-vaccine advocacy—must assess whether presented evidence supports a reasonable biological or epidemiological link. This takes time to do well, but less time than adversarial litigation. The British scheme redesign should invest in these expert panels and commit to timebound determinations.

Second, transparent communication of uncertainty. When causation remains genuinely unclear, we must say so. Not evasively. Not dismissively. But honestly. A reformed scheme should explicitly distinguish between: cases where causation is established; cases where causation is plausible but unproven; and cases where available evidence does not support a causal link. This transparency, paradoxically, builds trust. It shows respect for the questioner’s intelligence.

Third, parallel epidemiological surveillance. Every compensation claim should feed into active, independent pharmacovigilance systems. Not to deny claims, but to detect true signals. If a compensation scheme receives thirty claims of myocarditis within a defined population and timeframe, epidemiologists should know immediately. This is how we identify real harms early and adjust recommendations accordingly. The scheme becomes intelligence, not obstacle.

Fourth, international harmonization on process, not on outcomes. Different countries may reasonably compensate differently based on economic capacity and social values. But the process—standards of evidence, expert review, timelines, transparency—should converge. When other nations see the UK adopt rigorous but fair procedures, they will follow. This prevents a race to the bottom where compensation becomes a political rather than scientific exercise.

Why does this matter for Georgia, for Europe, for the global south? Because vaccine confidence is a public good that we all share. When one nation’s compensation scheme appears to reward speculation over investigation, hesitancy increases everywhere. Conversely, when a compensation scheme demonstrates that governments take harm seriously and evidence seriously, simultaneously, confidence in vaccination strengthens globally.

The critics who argue reform cannot succeed—who suggest compensation and confidence are incompatible—are wrong. But they are right that incompetence can destroy both. The path forward requires intellectual rigor, institutional courage, and unwavering commitment to evidence. It requires treating victims with justice and the public with respect.

Britain’s reform will be watched closely. Let us hope they design something worthy of that scrutiny.